Sutro Biopharma, Inc.
STRO
$1.10
-$0.02-1.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -67.70% | -113.31% | -112.99% | 28.12% | 12.76% |
| Total Depreciation and Amortization | 6.35% | 5.67% | 5.90% | 7.08% | 11.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.37% | 39.56% | -12.90% | -15.01% | 816.52% |
| Change in Net Operating Assets | -693.43% | 161.59% | 125.89% | -54.90% | -83.23% |
| Cash from Operations | -233.08% | -68.75% | -71.61% | 29.30% | -48.85% |
| Capital Expenditure | -6.23% | -0.18% | 28.20% | 44.38% | 55.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 248.68% | 4,213.91% | 56,576.73% | 1,020.83% | -719.68% |
| Cash from Investing | 243.76% | 2,000.21% | 5,668.50% | 687.69% | -969.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 67.34% | 42.34% | 17.34% |
| Issuance of Common Stock | -98.64% | 3,129.83% | 588.10% | 232.34% | 59.53% |
| Repurchase of Common Stock | 23.87% | 23.73% | -3.88% | 1.02% | 12.43% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -102.53% |
| Cash from Financing | -98.81% | -22.19% | -31.62% | -40.51% | -55.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.46% | 1,401.72% | 449.75% | 720.48% | -192.53% |